Description:
This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary
efficacy of AN0025 in combination with pembrolizumab in patients with locally
advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase
followed by an expansion phase. All enrolled patients will be treated with AN0025 and
Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or
withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of
pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of
AN0025 and in each cohort.
Title
- Brief Title: AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
- Official Title: An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
AN0025S0103
- SECONDARY ID:
2019-003960-37
- SECONDARY ID:
Keynote 879
- NCT ID:
NCT04432857
Conditions
- Triple-negative Breast Cancer
- NSCLC, Squamous or Non-Squamous
- Urothelial Carcinoma of the Bladder
- Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Cervical Cancer
Interventions
Drug | Synonyms | Arms |
---|
AN0025 | E7046 | Ph1a: Urothelial carcinoma of the bladder and NSCLC |
Pembrolizumab | Keytruda, MK3475-879 | Ph1a: Urothelial carcinoma of the bladder and NSCLC |
Purpose
This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary
efficacy of AN0025 in combination with pembrolizumab in patients with locally
advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase
followed by an expansion phase. All enrolled patients will be treated with AN0025 and
Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or
withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of
pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of
AN0025 and in each cohort.
Trial Arms
Name | Type | Description | Interventions |
---|
Ph1a: Urothelial carcinoma of the bladder and NSCLC | Experimental | Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks. | |
Phase 1b: Urothelial carcinoma of the bladder | Experimental | Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks. | |
Phase 1b: Non-Small Cell Lung Cancer (NSCLC) | Experimental | Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks. | |
Phase 1b: Triple-negative breast cancer (TNBC) | Experimental | Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks. | |
Phase 1b: Cervical | Experimental | Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks. | |
Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Experimental | Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks. | |
Eligibility Criteria
Inclusion Criteria:
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Diagnosed with histologically confirmed locally advanced and nonresectable, or metastatic
disease.
Phase 1a:
Patients with urothelial carcinoma of the bladder, or squamous or non-Squamous NSCLC
Phase 1b Expansion Cohort:
Patients diagnosed with one of the following tumor types:
A. Urothelial carcinoma of the bladder B. NSCLC, Squamous or Non-Squamous C. TNBC D.
Cervical cancer E. MSS CRC
Have progressed on treatment with an anti-PD-1/PD-L1monoclonal antibody (mAb) administered
either as monotherapy, or in combination with other checkpoint inhibitors or other
therapies (phase 1a, phase 1b cohort A or B) or with no prior anti-PD-1/PD-L1 therapy and
failed standard of care treatment (phase 1b cohort C, D, or E).
Have received no more than 3 prior lines of systemic therapy for advanced disease.
Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a
tumor lesion not previously irradiated.
Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple
gated acquisition (MUGA) scan.
Have adequate organ function.
Exclusion Criteria:
Have been discontinued treatment due to a Grade 3 or higher immune-related (irAE) from
prior anti-PD-1or anti-PD-L1, or with an agent directed to another stimulatory or
co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)
Have received prior systemic anti-cancer therapy including investigational agents within 4
weeks or 5 half-lives, whichever is shorter prior to treatment.
Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in
dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.
With a history of another primary malignancy within the past 2 years, with the exception of
basal or squamous cell skin cancer, or carcinoma in situ of the cervix or breast that has
undergone potentially curative therapy.
Have known active CNS metastases and/or carcinomatous meningitis.
Participants with known human immunodeficiency virus (HIV) and/or history of Hepatitis B or
C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus
(HBV) DNA or Hepatitis C Antibody or RNA.
Prolongation of corrected QT.
Significant cardiovascular impairment.
Inability to take oral medication, or malabsorption syndrome or any other uncontrolled
gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the
bioavailability of AN0025.
Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days after
the last dose of study treatment.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Primary Outcome Measure |
Time Frame: | 3 weeks |
Safety Issue: | |
Description: | Number of participants with Dose Limiting Toxicities (DLTs) |
Secondary Outcome Measures
Measure: | ORR and Progression-Free Survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Duration of Response (DOR) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Overall Survival (OS) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Efficacy by PD-L1 expression |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Adlai Nortye Biopharma Co., Ltd. |
Last Updated
May 28, 2021